

SEQUENCE LISTING

<110> Eli Lilly and Company

<120> Protein C polypeptide

<130> protein C truncated heavy chain

<140> x12279

<141> 1999-06-02

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 1244

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: recombinant human protein C truncated at C-terminus

<400> 1

```

gccaaactcct tcttggagga gctccgtcac agcagcctgg agcgggagtg catagaggag 60
atctgtgact tctaggagga caaggaaatt ttccaaaatg tggatgacac actggccttc 120
tggtccaagc acgtcgacgg tgaccagtgc ttggtcttgc ccttggagca cccgtgcgcc 180
agcctgtgct gggggcacgg cacgtgcacg gacggcatcg gcagcttcag ctgcgactgc 240
cgacagcggct gggaggccgg cttctgccag cgcgaggtga gcttcctcaa ttgctcgctg 300
gacaacggcg gctgcacgca ttactgcta gaggaggtgg gctggcggcg ctgtagctgt 360
gcgcctggct acaagctggg ggacgacctc ctgcagtgtc accccgcagt gaagtccct 420
tgtgggagga cctggaagcg gatggagaag aagcgcagtc acctgaaacg agacacagaa 480
gaccaagaag accaagtaga tccgcggctc attgatggga agatgaccag gcggggagac 540
agcccctggc aggtggtcct gctggactca aagaagaagc tggcctgcgg ggcagtgttc 600
atccacccct cctgggtgct gacagcggcc cactgcatgg atgagtccaa gaagctcctt 660
gtcaggcttg gagagtatga cctgcggcgc tgggagaagt gggagctgga cctggacatc 720
aaggaggtct tcttccccc caactacagc aagagcacca ccgacaatga catcgactg 780
ctgcacctgg ccagcccgcc caccctctcg cagaccatag tgcccatctg cctcccggac 840
agcggccttg cagagcgaga gctcaatcag gccggccagg agaccctcgt gacgggctgg 900
ggctaccaca gcagccgaga gaaggaggcc aagagaaacc gcacctcgt cctcaacttc 960
atcaagattc ccgtggtccc gcacaatgag tgcagcgagg tcatgagcaa catggtgtct 1020
gagaacatgc tgtgtgcggg catcctcggg gaccggcagg atgcctgoga gggcgacagt 1080
ggggggccca tggctgcctc cttccacggc acctggttcc tgggtggcct ggtgagctgg 1140
ggtgagggtc gtgggtcctc tcacaactac ggcgtttaca ccaaagtcag ccgctacctc 1200
gactggatcc atgggcacat cagagacaag gaagcccccc agaag 1245

```

<210> 2

<211> 415

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: recombinant
human protein C amino acid sequence with
C-terminus truncation

<400> 2

Ala Asn Ser Phe Leu Glu Glu Leu Arg His Ser Ser Leu Glu Arg Glu
1 5 10 15

Cys Ile Glu Glu Ile Cys Asp Phe Glu Glu Ala Lys Glu Ile Phe Gln
20 25 30

Asn Val Asp Asp Thr Leu Ala Phe Trp Ser Lys His Val Asp Gly Asp
35 40 45

Gln Cys Leu Val Leu Pro Leu Glu His Pro Cys Ala Ser Leu Cys Cys
50 55 60

Gly His Gly Thr Cys Ile Asp Gly Ile Gly Ser Phe Ser Cys Asp Cys
65 70 75 80

Arg Ser Gly Trp Glu Gly Arg Phe Cys Gln Arg Glu Val Ser Phe Leu
85 90 95

Asn Cys Ser Leu Asp Asn Gly Gly Cys Thr His Tyr Cys Leu Glu Glu
100 105 110

Val Gly Trp Arg Arg Cys Ser Cys Ala Pro Gly Tyr Lys Leu Gly Asp
115 120 125

Asp Leu Leu Gln Cys His Pro Ala Val Lys Phe Pro Cys Gly Arg Pro
130 135 140

Trp Lys Arg Met Glu Lys Lys Arg Ser His Leu Lys Arg Asp Thr Glu
145 150 155 160

Asp Gln Glu Asp Gln Val Asp Pro Arg Leu Ile Asp Gly Lys Met Thr
165 170 175

Arg Arg Gly Asp Ser Pro Trp Gln Val Val Leu Leu Asp Ser Lys Lys
180 185 190

Lys Leu Ala Cys Gly Ala Val Leu Ile His Pro Ser Trp Val Leu Thr
195 200 205

Ala Ala His Cys Met Asp Glu Ser Lys Lys Leu Leu Val Arg Leu Gly
 210 215 220

Glu Tyr Asp Leu Arg Arg Trp Glu Lys Trp Glu Leu Asp Leu Asp Ile
 225 230 235 240

Lys Glu Val Phe Val His Pro Asn Tyr Ser Lys Ser Thr Thr Asp Asn
 245 250 255

Asp Ile Ala Leu Leu His Leu Ala Gln Pro Ala Thr Leu Ser Gln Thr
 260 265 270

Ile Val Pro Ile Cys Leu Pro Asp Ser Gly Leu Ala Glu Arg Glu Leu
 275 280 285

Asn Gln Ala Gly Gln Glu Thr Leu Val Thr Gly Trp Gly Tyr His Ser
 290 295 300

Ser Arg Glu Lys Glu Ala Lys Arg Asn Arg Thr Phe Val Leu Asn Phe
 305 310 315 320

Ile Lys Ile Pro Val Val Pro His Asn Glu Cys Ser Glu Val Met Ser
 325 330 335

Asn Met Val Ser Glu Asn Met Leu Cys Ala Gly Ile Leu Gly Asp Arg
 340 345 350

Gln Asp Ala Cys Glu Gly Asp Ser Gly Gly Pro Met Val Ala Ser Phe
 355 360 365

His Gly Thr Trp Phe Leu Val Gly Leu Val Ser Trp Gly Glu Gly Cys
 370 375 380

Gly Leu Leu His Asn Tyr Gly Val Tyr Thr Lys Val Ser Arg Tyr Leu
 385 390 395 400

Asp Trp Ile His Gly His Ile Arg Asp Lys Glu Ala Pro Gln Lys
 405 410 415